Josh Riggs - Jan 17, 2023 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Interim CEO
Signature
/s/ Josh Riggs
Stock symbol
OCX
Transactions as of
Jan 17, 2023
Transactions value $
$0
Form type
4
Date filed
1/19/2023, 04:18 PM
Previous filing
Dec 9, 2022
Next filing
Feb 28, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +257K $0.00 257K Jan 17, 2023 Common Stock 257K $0.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will become exercisable in three equal installments on each of January 17, 2024, January 17, 2025 and January 17, 2026, subject to continuous service through the applicable vesting date.